Dry-eye expert Allergan bets $125M on Oculeve and its new implant approach

Allergan ($AGN) is adding to its dry-eye lineup with a new purchase agreement. The company has bet $125 million on a new approach to the disease, picking up Oculeve and lead candidate OD-01--a nerve-stimulating implant placed in the nose. More from FierceBiotech

Suggested Articles

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.

Merck and Roche are no strangers to sparring with their I-O meds Keytruda and Tecentriq, but in TNBC, Keytruda's latest data take the prize.

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.